ViroCell appoints Brian Collins as CFO
ViroCell appoints Brian Collins as CFO

Brian brings a wealth of relevant experience to the company as it embarks on its next phase of growth, having spent the last four years as CFO of the Cell and Gene Therapy Catapult

CDMO ViroCell Biologics has announced the appointment of Brian Collins as Chief Financial Officer (CFO).

Read More
Florence Buchanan
ViroCell appoints Brian Collins as CFO
ViroCell appoints Brian Collins as CFO

Brian’s appointment adds to an experienced leadership team that will drive ViroCell’s growth strategy to become a leading global specialist CDMO in cell and gene therapy

London, UK and New York, US, 26 July 2023 – ViroCell Biologics (“ViroCell” or the “Company”), a specialist Contract Development and Manufacturing Organisation (“CDMO”) in cell and gene therapy clinical trials, announces the appointment of Brian Collins as Chief Financial Officer (“CFO”).

Read More
Florence Buchanan
ViroCell accelerates forward with John Dawson CBE appointed as chairman
ViroCell accelerates forward with John Dawson CBE appointed as chairman

ViroCell Biologics announces the appointment of John A. Dawson CBE as chairman of the board of directors, facilitating the company's aspiration to be the global viral vector supplier of choice for novel cell and gene therapy clinical trials.

Key highlights:

  • John A. Dawson has been appointed as chairman of the board of directors for ViroCell.

  • The appointment validates the commercial opportunity for ViroCell and represents another milestone as the company builds towards becoming a global market leader in the viral vector clinical trial CDMO market.

  • In 2022 John was awarded a commander of the order of the British Empire (CBE) for services to U.K. life science by HM Queen Elizabeth II.

Read More
Florence Buchanan
ViroCell accelerates 2022 momentum with appointment of John A. Dawson CBE as Chairman of the Board of Directors
ViroCell accelerates 2022 momentum with appointment of John A. Dawson CBE as Chairman of the Board of Directors

ViroCell Biologics (“ViroCell”) today announces the appointment of John A. Dawson CBE as Chairman of the Board of Directors (“Chairman”).

ViroCell aspires to be the global viral vector supplier of choice for novel cell and gene therapy clinical trials. John’s appointment as Chairman further validates the commercial opportunity for ViroCell and represents another major milestone as we build towards becoming a global market leader in the viral vector clinical trial CDMO market.

Read More
Florence Buchanan